Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Mtor and PI3K Inhibitors Block Myeloma Cell Growth in a Synergistic Manner.

Andreas Guenther, Renate Burger, Wolfram Klapper, Markus Tiemann, Frank Bakker, Katja Brocke-Heidrich, Friedemann Horn, Martin Gramatzki

Blood (2009) 114 (22): 1843.

https://doi.org/10.1182/blood.V114.22.1843.1843

Published: 2009

Journal Articles

Interleukin-6–dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer

Dennis Löffler, Katja Brocke-Heidrich, Gabriele Pfeifer, Claudia Stocsits, Jörg Hackermüller, Antje K. Kretzschmar, Renate Burger, Martin Gramatzki, Conny Blumert, Kay Bauer, Helena Cvijic, A. Kerstin Ullmann, Peter F. Stadler, Friedemann Horn

Blood (2007) 110 (4): 1330–1333.

https://doi.org/10.1182/blood-2007-03-081133

Published: 2007

Includes: Supplemental data

Journal Articles

Inhibitors of mToR Mediate Anti-Myeloma Activity by Apoptosis through the Extrinsic Pathway.

Andreas Günther, MD, Markus Tiemann, M.D., Frank Bakker, Ph.D., Wolfgang Baum, Ph.D., Katja Brocke-Heidrich, Ph.D., Friedemann Horn, Ph.D., Renate Burger, Ph.D., Martin Gramatzki, M.D.

Blood (2006) 108 (11): 3428.

https://doi.org/10.1182/blood.V108.11.3428.3428

Published: 2006

Journal Articles

Interleukin-6–dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family–independent survival pathway closely associated with Stat3 activation

Katja Brocke-Heidrich, Antje K. Kretzschmar, Gabriele Pfeifer, Christian Henze, Dennis Löffler, Dirk Koczan, Hans-Jürgen Thiesen, Renate Burger, Martin Gramatzki, Friedemann Horn

Blood (2004) 103 (1): 242–251.

https://doi.org/10.1182/blood-2003-04-1048

Published: 2004

Includes: Supplemental data

Journal Articles

Is hemophagocytic lymphohistiocytosis an autoimmune disease?

Volker Schuster, Friedemann Horn, Michael Borte

Blood (2002) 100 (7): 2677.

https://doi.org/10.1182/blood-2002-05-1411

Published: 2002

NARROW

Mtor and PI3K Inhibitors Block Myeloma Cell Growth in a Synergistic Manner.

Interleukin-6–dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer

Inhibitors of mToR Mediate Anti-Myeloma Activity by Apoptosis through the Extrinsic Pathway.

Interleukin-6–dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family–independent survival pathway closely associated with Stat3 activation

Is hemophagocytic lymphohistiocytosis an autoimmune disease?

Email alerts

ASH Publications

American Society of Hematology

Mtor and PI3K Inhibitors Block Myeloma Cell Growth in a Synergistic Manner.

Interleukin-6–dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer

Inhibitors of mToR Mediate Anti-Myeloma Activity by Apoptosis through the Extrinsic Pathway.

Interleukin-6–dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family–independent survival pathway closely associated with Stat3 activation

Is hemophagocytic lymphohistiocytosis an autoimmune disease?

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only